Results 1 to 10 of about 459,821 (133)

NGLY1 Deficiency: A Rare Newly Described Condition with a Typical Presentation [PDF]

open access: yesLife, 2021
NGLY1 deficiency is the first recognized autosomal recessive disorder of N-linked deglycosylation (NGLY1-CDDG). This severe multisystemic disease is still poorly known and, to date, most cases have been diagnosed through whole exome or genome sequencing.
Ivana Dabaj   +12 more
doaj   +8 more sources

Reversibility of motor dysfunction in the rat model of NGLY1 deficiency [PDF]

open access: yesMolecular Brain, 2021
N-glycanase 1 (NGLY1) deficiency is a rare inherited disorder characterized by developmental delay, hypolacrima or alacrima, seizure, intellectual disability, motor deficits, and other neurological symptoms.
Makoto Asahina   +5 more
doaj   +6 more sources

AAV9-NGLY1 gene replacement therapy improves phenotypic and biomarker endpoints in a rat model of NGLY1 Deficiency [PDF]

open access: yesMolecular Therapy: Methods & Clinical Development, 2022
N-glycanase 1 (NGLY1) Deficiency is a progressive, ultra-rare, autosomal recessive disorder with no approved therapy and five core clinical features: severe global developmental delay, hyperkinetic movement disorder, elevated liver transaminases ...
Lei Zhu   +9 more
doaj   +6 more sources

NGLY1 Deficiency Zebrafish Model Manifests Abnormalities of the Nervous and Musculoskeletal Systems [PDF]

open access: yesFrontiers in Cell and Developmental Biology, 2022
Background: NGLY1 is an enigmatic enzyme with multiple functions across a wide range of species. In humans, pathogenic genetic variants in NGLY1 are linked to a variable phenotype of global neurological dysfunction, abnormal tear production, and liver ...
Aviv Mesika   +11 more
doaj   +6 more sources

NGLY1 Deficiency, a Congenital Disorder of Deglycosylation: From Disease Gene Function to Pathophysiology [PDF]

open access: yesCells, 2022
N-Glycanase 1 (NGLY1) is a cytosolic enzyme involved in removing N-linked glycans of misfolded N-glycoproteins and is considered to be a component of endoplasmic reticulum-associated degradation (ERAD).
Ashutosh Pandey   +3 more
doaj   +5 more sources

NGLY1 deficiency—A rare congenital disorder of deglycosylation [PDF]

open access: yesJIMD Reports, 2020
Pathogenic variants in the NGLY1 gene are associated with a Congenital Disorder of Deglycosylation (CDDG) characterized by delays in reaching developmental milestones, complex hyperkinetic movement disorder, transient elevation of transaminases, and ...
Patrícia Lipari Pinto   +6 more
doaj   +5 more sources

NGLY1 deficiency: Novel patient, review of the literature and diagnostic algorithm [PDF]

open access: yesJIMD Reports, 2020
Objectives Together with the lysosomal storage diseases, NGLY1 deficiency is a congenital disorder of deglycosylation (NGLY1‐CDDG). Since the first report in 2012, 26 patients have been described. All but one were diagnosed by exome or genome sequencing;
Patryk Lipiński   +4 more
doaj   +6 more sources

Preclinical pharmacology and safety studies to support an AAV9 NGLY1 gene therapy clinical trial for the treatment of NGLY1 deficiency [PDF]

open access: yesMolecular Therapy: Methods & Clinical Development
GS-100 is an AAV9 gene replacement therapy for the treatment of N-glycanase 1 (NGLY1) deficiency, an ultra-rare, recessive disorder characterized by developmental delay, intellectual disability, hyperkinetic movement disorder, elevated liver enzymes ...
Lei Zhu   +7 more
doaj   +6 more sources

NGLY1 deficiency: estimated incidence, clinical features, and genotypic spectrum from the NGLY1 Registry [PDF]

open access: yesOrphanet Journal of Rare Diseases, 2022
Purpose NGLY1 Deficiency is an ultra-rare, multisystemic disease caused by biallelic pathogenic NGLY1 variants. The aims of this study were to (1) characterize the variants and clinical features of the largest cohort of NGLY1 Deficiency patients reported
Caroline R. Stanclift   +8 more
doaj   +4 more sources

An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency [PDF]

open access: yesPLoS Genetics, 2022
NGLY1 deficiency, a rare disease with no effective treatment, is caused by autosomal recessive, loss-of-function mutations in the N-glycanase 1 (NGLY1) gene and is characterized by global developmental delay, hypotonia, alacrima, and seizures.
Kevin A. Hope   +3 more
doaj   +4 more sources

Home - About - Disclaimer - Privacy